Hyperliquid Strategies Inc completed a business combination with Sonnet BioTherapeutics, creating a digital asset treasury reserve company. The merged entity will trade under the ticker 'PURR' on Nasdaq and aims to provide investors exposure to the HYPE token ecosystem.

Sonnet BioTherapeutics Holdings has received stockholder approval for its proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC, marking a significant corporate development for the oncology-focused biotechnology company.

Heights Capital Management established a new $16.15 million position in ImmunityBio, buying 6,565,709 shares, representing 4.4% of its assets under management. The investment suggests potential confidence in the company's clinical-stage immunotherapy pipeline.

Sonnet BioTherapeutics, a clinical-stage oncology company, will present at the MedInvest Biotech & Pharma Conference. The company is developing immunotherapeutic drugs using its FHAB platform, with lead program SON-1010 being studied for ovarian cancer treatment in collaboration with Roche.

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for three companies: Sonnet BioTherapeutics, First Community Corporation, and Monogram Technologies, related to their recent merger or sale transactions.